Zydus Lifesciences Ltd - Company Profile
Powered by 
All the data and insights you need on Zydus Lifesciences Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Zydus Lifesciences Ltd Strategy Report
- Understand Zydus Lifesciences Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Zydus Lifesciences Ltd (Zydus Lifesciences) formerly Cadila Healthcare Ltd, is an integrated global healthcare provider. It discovers, develops, manufactures and commercializes various healthcare products. The company’s product portfolio includes active pharmaceutical ingredients (APIs), formulations, wellness and animal health products. Zydus Lifesciences products find application in the treatment of diseases in the therapeutic areas of gastrointestinal, cardiovascular, respiratory, pain management, cancer, inflammation, neurology, and women's health, among others. It conducts research to develop biologics, biosimilars, vaccines and new chemical entities. The company has manufacturing facilities in Gujarat, Goa, Maharashtra, Sikkim and Himachal Pradesh in India; Brazil and the US. It has presence in the US, Europe, South Africa, Japan, Brazil, and other emerging markets. Zydus Lifesciences is headquartered in Ahmedabad, Gujarat, India.
Headquarters
India
Address
Zydue Tower, Satellite Cross Road, Ahmedabad, Gujarat, 382481
Website
www.zyduslife.com/zyduslife
Telephone
91 79 26868100
No of Employees
23,026
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ZYDUSLIFE (NSE)
Revenue (2022)
$2.2B
14.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-56.3%
(2022 vs 2021)
Market Cap*
$11.4B
Net Profit Margin (2022)
XYZ
-61.7%
(2022 vs 2021)
* As of and is in US$
Zydus Lifesciences Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Generic Biosimilars | OCID QRS |
| Generics Drugs | ATEN |
| Formulations | FALCIGO |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In April, Sentynl Therapeutics, Inc. received approval from The Medicines and Healthcare products Regulatory Agency for NULIBRY (fosdenopterin) for Injection as the first therapy for the treatment of patients in Great Britain with molybdenum cofactor deficiency. |
| 2024 | New Products/Services | In March, the company introduced Olaparib, a PARP inhibitor. |
| 2024 | Plans/Strategy | In January, the company announced its plans to invest INR 5,000 crore in Gujarat, India. |
Competitor Comparison
| Key Parameters | Zydus Lifesciences Ltd | Sun Pharmaceutical Industries Ltd | Dr. Reddy's Laboratories Ltd | Cipla Ltd | Lupin Ltd |
|---|---|---|---|---|---|
| Headquarters | India | India | India | India | India |
| City | Ahmedabad | Mumbai | Hyderabad | Mumbai | Mumbai |
| State/Province | Gujarat | Maharashtra | Telangana | Maharashtra | Maharashtra |
| No. of Employees | 23,026 | 41,000 | 24,832 | 26,615 | 18,971 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Pankaj R. Patel | Chairman | Executive Board | 2002 | 70 |
| Sharvil P. Patel, Ph.D. | Director; Managing Director - Deputy | Executive Board | 2007 | 45 |
| Ganesh N. Nayak | Director | Executive Board | 2020 | 68 |
| Nitin D. Parekh | Chief Financial Officer | Senior Management | 2009 | - |
| Punit Patel | Chief Executive Officer - Americas; President - Americas | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward